Is BIIB stock a Buy, Sell, or Hold?

Based on our analysis, BIIB is currently a HOLD with moderate confidence. 📊 HOLD: BIIB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of BIIB stock?

Our analysis estimates the fair value range for BIIB to be between $199.38 and $208.66. The current price is $209.83.

What is the analyst price target for BIIB?

The average Wall Street analyst price target for BIIB is $235.57. This implies a potential upside of 12.3% from current levels.

BIIB Stock Analysis: Buy, Sell, or Hold?

BIIB - Biogen Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

$209.83

-0.82 (-0.39%) ▼

5d: +0.91%

30d: +0.44%

90d: +9.65%

HOLD

MODERATE Confidence

Protect Your BIIB Gains

Analysis Updated: Aug 14, 2026 12:00 AM ET

Earnings: Jul 29, 2026 0d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Aug 12, 2026 at $208.87 · last confirmed Aug 12, 2026

Strength: 5.6/10

Get Alerted When BIIB Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: BIIB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$381.52

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$236.89

11.4% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.8x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: BIIB is currently trading at $209.83, which is considered extended relative to its 30-day fair value range of $199.38 to $208.66. The stock's valuation (Forward PE: 12.6) is in line with its historical norms (11.8). At these levels, the market is pricing in 2.4% annual earnings growth.

Technical Outlook: Technically, BIIB is in a strong uptrend. The price is approaching resistance at $215.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $235.57 (+12.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position EXTENDED

Historical Trading Range $199.38 - $208.66

Company Quality Score 55/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 61.2%

Protect Your Profits

Holding BIIB? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BEARISH: Price extended above range
BULLISH: Options cheap (IV 0th percentile)
NEUTRAL: Mixed technical signals (56/100)
BULLISH: High volume confirmation
BULLISH: Trading below Wall St target ($235.57)
BULLISH: Expecting earnings turnaround to 2.4% growth with 3.4% revenue growth
NEUTRAL: Bottoming setup forming (56/100) — watch for confirmation

Trading Range Analysis

30-Day Trading Range $199.38 - $208.66

Current vs Trading Range EXTENDED

Expected Move (7 Days) ±$9.45 (4.5%)

Support & Resistance Levels

Support Level $199.58

Resistance Level $215.61

Current Trend Strong Uptrend

Technical data as of Aug 14, 2026

Fundamental Context

Forward P/E (Next Year Est.) 12.64

Wall Street Target $235.57 (+12.3%)

Revenue Growth (YoY) 3.4%

Earnings Growth (YoY) -84.8%

Profit Margin 8.3%

Valuation Premium vs History +2.4% premium

PE vs Historical 12.6 vs 11.8 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +2.4% (market-implied from PE analysis)

1-Year Target $214.87 (+2%)

2-Year Target $220.02 (+5%)

3-Year Target $225.30 (+7%)

3-Yr Target (if PE normalizes) (PE: 13→12) PE COMPRESSION $210.36 (+0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.2, Growth: 33.4%) $798.24 (+280%)

Base: (SPY PE: 12.6, Growth: 33.4%) $498.68 (+138%)

Bear: (PE: 10.7, Growth: 33.4%) $423.88 (+102%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (37x PE), but valuation improves significantly next year (13x PE) as earnings recover.

Trailing PE: 37.02 | Current EPS (TTM): $5.69

Bull Case $463.43 (+121%)

Analyst growth 100.0%, PE expands to 40.7

Base Case $421.30 (+101%)

Market implied 100.0%, PE stable at 37.0

Bear Case $143.24 (-32%)

Severe decline -20.0%, PE contracts to 31.5

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: August 16, 2026 2:11 AM ET
Data refreshes hourly during market hours. Next update: 3:11 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is BIIB showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for BIIB.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1297	41 HOLD
ABBV AbbVie Inc	BUY 28 analysts	$274	66 BUY
GILD Gilead Sciences Inc	BUY 30 analysts	$157	44 HOLD
MRK Merck & Company Inc	BUY 26 analysts	$137	46 HOLD
AMGN Amgen Inc	HOLD 32 analysts	$375	36 SELL

LLY Eli Lilly and Com…

41 HOLD

ABBV AbbVie Inc

66 BUY

GILD Gilead Sciences I…

44 HOLD

MRK Merck & Company I…

46 HOLD

AMGN Amgen Inc

36 SELL

Advanced BIIB Option Strategies

Professional options setups generated by AI based on today's BIIB price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for BIIB

BIIB Technical Chart BIIB Price Prediction BIIB Earnings Date BIIB Investment Advisor BIIB Fair Price Analyzer BIIB Options Advisor BIIB Options Chain BIIB Options Analysis BIIB Competitors

Compare BIIB with Peers

BIIB vs REGN
Which one to buy?

BIIB vs AMGN
Which one to buy?

BIIB vs GILD
Which one to buy?

BIIB vs VRTX
Which one to buy?

BIIB vs ILMN
Which one to buy?

AZN vs BIIB
Winner: Tie

ABSI vs BIIB
Winner: BIIB

AURA vs BIIB

Create New Comparison View All Competitors

Tradestie